Cargando…
Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial
PURPOSE: Constipation can be a significant problem in critically unwell patients, associated with detrimental outcomes. Opioids are thought to contribute to the mechanism of bowel dysfunction. We tested if methylnaltrexone, a pure peripheral mu-opioid receptor antagonist, could reverse opioid-induce...
Autores principales: | Patel, Parind B., Brett, Stephen J., O’Callaghan, David, Anjum, Aisha, Cross, Mary, Warwick, Jane, Gordon, Anthony C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223905/ https://www.ncbi.nlm.nih.gov/pubmed/32016532 http://dx.doi.org/10.1007/s00134-019-05913-6 |
Ejemplares similares
-
Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)
por: Patel, Parind B, et al.
Publicado: (2016) -
Methylnaltrexone in the treatment of opioid-induced constipation
por: Meerveld, Beverley Greenwood-Van, et al.
Publicado: (2008) -
Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
por: Deibert, Peter, et al.
Publicado: (2010) -
Methylnaltrexone and Naloxone for Opioid-induced Constipation in the Critical Care Setting
por: Saini, Harneel S, et al.
Publicado: (2020) -
Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide
por: Bader, S., et al.
Publicado: (2011)